Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial
Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Early Relapse in Multiple Myeloma Linked to Greater Economic Burden in US
Multiple myeloma patients whose cancer progresses early after first-line…
Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows
Twice‐weekly Ninlaro (ixazomib) plus Revlimid…
Kyprolis Label to Include Positive Data of Aspire Trial in Advanced Multiple Myeloma Patients
Prescribing information for Kyprolis (carfilzomib) in the U.S. will…
Advanced Blood Sample Analysis Could Be Better Than Bone Marrow Biopsies, Study Shows
Genetic analysis of multiple myeloma DNA from two different…
Empliciti Triple Combo Delays Disease Progression in Advanced Myeloma Patients, Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and…
